Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARM Carisma Therapeutics	$0.50 +11.6%	$0.26	$0.14 ▼ $1.90	$20.99M	1.63	3.77 million shs	2.90 million shs
DRMA Dermata Therapeutics	$0.69 -1.9%	$0.76	$0.65 ▼ $5.00	$4.43M	0.57	1.18 million shs	132,909 shs
GELS Gelteq	$1.81 -1.6%	$1.73	$0.77 ▼ $5.50	$17.08M	N/A	4.00 million shs	64,536 shs
GOVX GeoVax Labs	$0.92 +2.7%	$1.00	$0.73 ▼ $11.18	$14.05M	3.45	1.22 million shs	12.85 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARM Carisma Therapeutics	+11.62%	-16.73%	+164.09%	+20.80%	-51.23%
DRMA Dermata Therapeutics	-1.91%	-10.32%	-16.37%	-41.18%	-72.01%
GELS Gelteq	-1.63%	-22.65%	-3.72%	+84.45%	+180,999,900.00%
GOVX GeoVax Labs	+2.74%	-18.89%	-9.34%	-31.50%	-51.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CARM Carisma Therapeutics	2.4726 of 5 stars	3.2	5.0	0.0	0.0	0.6	1.7	0.6
DRMA Dermata Therapeutics	2.1023 of 5 stars	3.5	5.0	0.0	0.0	0.6	0.8	0.0
GELS Gelteq	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	3.0921 of 5 stars	3.6	4.0	0.0	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARM Carisma Therapeutics	2.43	Hold	$1.93	283.24% Upside
DRMA Dermata Therapeutics	3.00	Buy	$3.00	332.21% Upside
GELS Gelteq	0.00	N/A	N/A	N/A
GOVX GeoVax Labs	3.29	Buy	$11.10	1,100.39% Upside

Current Analyst Ratings Breakdown

Latest DRMA, GELS, CARM, and GOVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/21/2025	DRMA Dermata Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00
5/2/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $9.00
4/16/2025	GOVX GeoVax Labs	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/15/2025	GOVX GeoVax Labs	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.50
4/10/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/1/2025	CARM Carisma Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $1.00
3/28/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARM Carisma Therapeutics	$19.63M	1.07	N/A	N/A	($0.67) per share	-0.75
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	$0.62 per share	N/A
GELS Gelteq	$100K	170.86	N/A	N/A	N/A	∞
GOVX GeoVax Labs	$3.95M	3.56	N/A	N/A	$0.48 per share	1.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARM Carisma Therapeutics	-$60.48M	-$1.56	N/A	N/A	N/A	-254.28%	-957.20%	-137.38%	8/6/2025 (Estimated)
DRMA Dermata Therapeutics	-$12.29M	-$16.41	N/A	∞	N/A	N/A	-270.81%	-179.96%	8/6/2025 (Estimated)
GELS Gelteq	-$2.33M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	-$24.99M	-$3.65	N/A	N/A	N/A	-438.20%	-511.96%	-286.58%	8/5/2025 (Estimated)

Latest DRMA, GELS, CARM, and GOVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	DRMA Dermata Therapeutics	-$0.45	-$0.45	N/A	-$0.45	N/A	N/A
5/13/2025	Q1 2025	CARM Carisma Therapeutics	-$0.17	-$0.22	-$0.05	-$0.22	$2.47 million	$3.65 million
5/1/2025	Q1 2025	GOVX GeoVax Labs	-$0.59	-$0.45	+$0.14	-$0.45	$0.75 million	$1.64 million
3/27/2025	Q4 2024	GOVX GeoVax Labs	-$0.79	-$0.30	+$0.49	-$0.30	$2.38 million	$3.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A
GELS Gelteq	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARM Carisma Therapeutics	N/A	1.34	1.34
DRMA Dermata Therapeutics	N/A	3.70	3.70
GELS Gelteq	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	3.62	3.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CARM Carisma Therapeutics	44.27%
DRMA Dermata Therapeutics	8.67%
GELS Gelteq	N/A
GOVX GeoVax Labs	6.09%

Insider Ownership

Company	Insider Ownership
CARM Carisma Therapeutics	12.57%
DRMA Dermata Therapeutics	18.50%
GELS Gelteq	N/A
GOVX GeoVax Labs	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CARM Carisma Therapeutics	20	41.79 million	36.54 million	No Data
DRMA Dermata Therapeutics	8	6.38 million	5.20 million	Not Optionable
GELS Gelteq	N/A	9.44 million	N/A	N/A
GOVX GeoVax Labs	10	15.19 million	15.01 million	Not Optionable

DRMA, GELS, CARM, and GOVX Headlines

Recent News About These Companies

GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting

June 17 at 9:33 AM | finance.yahoo.com

D. Boral Capital Reiterates "Buy" Rating for GeoVax Labs (NASDAQ:GOVX)

June 17 at 2:53 AM | americanbankingnews.com

GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA

June 16 at 9:57 AM | finance.yahoo.com

GeoVax to Participate in BIO International Convention 2025

June 12, 2025 | finance.yahoo.com

GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency

June 11, 2025 | finance.yahoo.com

GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia

June 9, 2025 | finance.yahoo.com

GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing

May 29, 2025 | finance.yahoo.com

GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance

May 27, 2025 | finance.yahoo.com

GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation

May 21, 2025 | finance.yahoo.com

GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production

May 6, 2025 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and Baxter International (BAX)

May 5, 2025 | theglobeandmail.com

Geovax highlights progress on mpox vaccine and COVID-19 trial advancements

May 2, 2025 | msn.com

GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update

May 2, 2025 | finance.yahoo.com

GeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call Transcript

May 1, 2025 | seekingalpha.com

Geovax Labs is a buy, Roth says

April 29, 2025 | cantechletter.com

GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater

April 25, 2025 | theglobeandmail.com

EQS-News: GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress

April 24, 2025 | markets.businessinsider.com

GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress

April 24, 2025 | finance.yahoo.com

GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations

April 22, 2025 | finance.yahoo.com

EQS-News: GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations

April 22, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA, GELS, CARM, and GOVX Company Descriptions

Carisma Therapeutics NASDAQ:CARM

$0.50 +0.05 (+11.62%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$0.48 -0.02 (-3.64%)

As of 06/18/2025 07:57 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Dermata Therapeutics NASDAQ:DRMA

$0.69 -0.01 (-1.91%)

Closing price 06/18/2025 03:49 PM Eastern

Extended Trading

$0.69 -0.01 (-1.02%)

As of 06/18/2025 07:40 PM Eastern

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Gelteq NASDAQ:GELS

$1.81 -0.03 (-1.63%)

As of 06/18/2025 04:00 PM Eastern

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

GeoVax Labs NASDAQ:GOVX

$0.92 +0.02 (+2.74%)

As of 06/18/2025 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time